Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Lessons prom the PROVE-IT trial - Higher dose of potent statin better for high-risk patients

Lessons prom the PROVE-IT trial - Higher dose of potent statin better for high-risk patients CLEVELAND CLINIC JOURNAL OF MEDICINE Khush, K. K., Waters, D. 2004; 71 (8): 609-616

Abstract

The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.

View details for Web of Science ID 000223379600003

View details for PubMedID 15449756